NEWS

BeadReady™ successfully storing cells for 3D biofabrication - Read our latest publication

BeadReady™ successfully storing cells for 3D bi...

Another fantastic publication highlighting one of the multiple applications Atelerix products have within the scientific research and development industry. Anastassia Kostenko , Che J. Connon, and Stephen Swioklo (2023), have...

BeadReady™ successfully storing cells for 3D bi...

Another fantastic publication highlighting one of the multiple applications Atelerix products have within the scientific research and development industry. Anastassia Kostenko , Che J. Connon, and Stephen Swioklo (2023), have...

GBIP Canada Application Success

GBIP Canada Application Success

Atelerix has been awarded a place on the Global Business Innovation Programme for Biomanufacturing of Biologics and Advanced Therapies in Canada. Organised by Innovate UK and delivered by Innovate UK...

GBIP Canada Application Success

Atelerix has been awarded a place on the Global Business Innovation Programme for Biomanufacturing of Biologics and Advanced Therapies in Canada. Organised by Innovate UK and delivered by Innovate UK...

Press Release: Strategic partnership for market expansion

Press Release: Strategic partnership for market...

Atelerix Limited, which develops and markets innovative solutions for the storage and transport of cells, tissues, and viruses at hypothermic temperature (without freezing) is pleased to announce they have signed...

Press Release: Strategic partnership for market...

Atelerix Limited, which develops and markets innovative solutions for the storage and transport of cells, tissues, and viruses at hypothermic temperature (without freezing) is pleased to announce they have signed...

New Publication Announcement!

New Publication Announcement!

Following on from LVPEI's successful proof of concept studies highlighting the successful use of Atelerix's technology to distribute a limbal-stromal cell therapy throughout India (Damala et al., 2019), we are delighted to announce the...

New Publication Announcement!

Following on from LVPEI's successful proof of concept studies highlighting the successful use of Atelerix's technology to distribute a limbal-stromal cell therapy throughout India (Damala et al., 2019), we are delighted to announce the...

CytoStor™ successfully preserves primary human Liver Sinusoidal Endothelial cells (LSEC)

CytoStor™ successfully preserves primary human ...

The liver microenvironment is proving to be a major obstacle to the success of immunotherapy in solid organ tumours. The liver is characterised by tolerogenic properties that lead to the...

CytoStor™ successfully preserves primary human ...

The liver microenvironment is proving to be a major obstacle to the success of immunotherapy in solid organ tumours. The liver is characterised by tolerogenic properties that lead to the...

Atelerix presents promising data for the application of its technology LeukoStor™ to Monocyte Preservation

Atelerix presents promising data for the applic...

Peripheral blood mononuclear cells (PBMCs), derived from whole blood or leukapheresis, encompass several major immune cell populations including lymphocytes, monocytes, NK cells and dendritic cells. Apheresis material is a PBMC-enriched...

Atelerix presents promising data for the applic...

Peripheral blood mononuclear cells (PBMCs), derived from whole blood or leukapheresis, encompass several major immune cell populations including lymphocytes, monocytes, NK cells and dendritic cells. Apheresis material is a PBMC-enriched...